nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.12.2021 | Neurotrauma (D. Sandsmark, Section Editor)

The Role of HMGB1 in Traumatic Brain Injury—Bridging the Gap Between the Laboratory and Clinical Studies

verfasst von: S Manivannan, E Wales, M Zaben

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Traumatic brain injury (TBI) is amongst the leading causes of mortality and morbidity worldwide. However, several pharmacological strategies in the clinical setting remain unsuccessful. Mounting evidence implicates High Mobility Group Box protein 1 (HMGB1) as a unique alternative target following brain injury. Herein, we discuss current understanding of HMGB1 in TBI and obstacles to clinical translation.

Recent Findings

HMGB1 plays a pivotal role as a ‘master-switch’ of neuro-inflammation following injury and in the regulation of neurogenesis during normal development. Animal models point towards the involvement of HMGB1 signalling in prolonged activation of glial cells and widespread neuronal death. Early experimental studies demonstrate positive effects of HMGB1 antagonism on both immunohistochemical and neuro-behavioural parameters following injury. Raised serum/CSF HMGB1 in humans is associated with poor outcomes post-TBI.

Summary

HMGB1 is a promising therapeutic target post-TBI. However, further studies elucidating receptor, cell, isoform, and temporal effects are required prior to clinical translation.

Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morbidity and mortality weekly report. 2009;58(16):421-6.

Ghawami H, Sadeghi S, Raghibi M, Rahimi-Movaghar V. Executive functioning of complicated-mild to moderate traumatic brain injury patients with frontal contusions. Appl Neuropsychol Adult. 2016:1–9. https://doi.org/10.1080/23279095.2016.1157078.

Nygren DeBoussard C, Lannsjo M, Stenberg M, Stalnacke BM, Godbolt AK. Behavioural problems in the first year after severe traumatic brain injury: a prospective multicentre study. Clin Rehabil. 2017;31(4):555–66. https://doi.org/10.1177/0269215516652184.CrossRefPubMed

Lewis FD, Horn GJ. Depression following traumatic brain injury: impact on post-hospital residential rehabilitation outcomes. Neuro Rehabilit. 2017. https://doi.org/10.3233/NRE-161427.

Chan RC, Hoosain R, Lee TM, Fan YW, Fong D. Are there sub-types of attentional deficits in patients with persisting post-concussive symptoms? A cluster analytical study. Brain Inj. 2003;17(2):131–48. https://doi.org/10.1080/0269905021000010168.CrossRefPubMed

Simon DW, McGeachy MJ, Bayır H, Clark RSB, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nature Rev Neurol. 2017;13(9):572. https://doi.org/10.1038/nrneurol.2017.116.CrossRef

Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of traumatic brain injury: time for a paradigm shift. Neuron. 2017;95(6):1246–65. https://doi.org/10.1016/j.neuron.2017.07.010.CrossRefPubMedPubMedCentral

Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere Querini P, Venereau E. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 2017;280(1):74–82. https://doi.org/10.1111/imr.12601.CrossRefPubMed

Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270(43):25752–61. https://doi.org/10.1074/jbc.270.43.25752.CrossRefPubMed

10.

Ueda T, Yoshida M. HMGB proteins and transcriptional regulation. Biochimica et Biophysica Acta. 2010;1799(1-2):114–8. https://doi.org/10.1016/j.bbagrm.2009.11.005.CrossRefPubMed

11.

Fink MP. Bench-to-bedside review: high-mobility group box 1 and critical illness. Crit Care (London, England). 2007;11(5):229. https://doi.org/10.1186/cc6088.CrossRef

12.

Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, et al. High mobility group 1 B-box mediates activation of human endothelium. J Internal Med. 2003;254(4):375–85. https://doi.org/10.1046/j.1365-2796.2003.01204.x.CrossRefPubMed

13.

He M, Bianchi ME, Coleman TR, Tracey KJ, Al-Abed Y. Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance. Mol Med. 2018;24(1):21. https://doi.org/10.1186/s10020-018-0023-8.CrossRefPubMedPubMedCentral

14.

•• Manivannan S, Marei O, Elalfy O, Zaben M. Neurogenesis after traumatic brain injury - The complex role of HMGB1 and neuroinflammation. Neuropharmacology. 2021;183:108400. https://doi.org/10.1016/j.neuropharm.2020.108400Narrative review summarising the dual role of HMGB1 in brain injury and neurogenesis. Effects of concentration, context, HMGB1 isoforms, and target receptors are discussed.CrossRefPubMed

15.

Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clinica Chimica Acta; Int J Clin Chem. 2012;413(21-22):1737–41. https://doi.org/10.1016/j.cca.2012.07.002.CrossRef

16.

Au AK, Aneja RK, Bell MJ, Bayir H, Feldman K, Adelson PD, et al. Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury. J Neurotrauma. 2012;29(11):2013–21. https://doi.org/10.1089/neu.2011.2171.CrossRefPubMedPubMedCentral

17.

Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–5. https://doi.org/10.1038/nature00858.CrossRefPubMed

18.

Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B, et al. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia. 2014;62(1):26–38. https://doi.org/10.1002/glia.22581.CrossRefPubMed

19.

•• Manivannan S, Harari B, Muzaffar M, Elalfy O, Hettipathirannahelage S, James Z, et al. Glycyrrhizin Blocks the Detrimental Effects of HMGB1 on Cortical Neurogenesis After Traumatic Neuronal Injury. Brain Sci. 2020;10(10):760. https://doi.org/10.3390/brainsci10100760In vitro study demonstrating that HMGB1 release following traumatic injury reduces neuronal numbers/proportions in primary neural stem cell/progenitor cultures via RAGE-dependent effect. Indicates that HMGB1 release post-TBI may hinder cortical neurogenesis.CrossRefPubMedCentral

20.

Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem. 2007;103(2):590–603. https://doi.org/10.1111/j.1471-4159.2007.04788.x.CrossRefPubMed

21.

Braun M, Vaibhav K, Saad NM, Fatima S, Vender JR, Baban B, et al. White matter damage after traumatic brain injury: a role for damage associated molecular patterns. Biochim Biophys Acta Mol Basis Dis. 2017;1863(10 Pt B):2614–26. https://doi.org/10.1016/j.bbadis.2017.05.020.CrossRefPubMed

22.

Chen X, Wu S, Chen C, Xie B, Fang Z, Hu W, et al. Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-kappaB pathway following experimental traumatic brain injury. J Neuroinflammation. 2017;14(1):143. https://doi.org/10.1186/s12974-017-0917-3.CrossRefPubMedPubMedCentral

23.

Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22(20):5551–60. https://doi.org/10.1093/emboj/cdg516.CrossRefPubMedPubMedCentral

24.

Gao T, Chen Z, Chen H, Yuan H, Wang Y, Peng X, et al. Inhibition of HMGB1 mediates neuroprotection of traumatic brain injury by modulating the microglia/macrophage polarization. Biochem Biophys Res Commun. 2018;497(1):430–6. https://doi.org/10.1016/j.bbrc.2018.02.102.CrossRefPubMed

25.

Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al. Microglial and macrophage polarization—new prospects for brain repair. Nature Rev Neurol. 2015;11(1):56–64. https://doi.org/10.1038/nrneurol.2014.207.CrossRef

26.

Wang L, Wu J, Guo X, Huang X, Huang Q. RAGE plays a role in LPS-induced NF-κB activation and endothelial hyperpermeability. Sensors (Basel, Switzerland). 2017;17(4):722. https://doi.org/10.3390/s17040722.CrossRef

27.

Okuma Y, Liu K, Wake H, Liu R, Nishimura Y, Hui Z, et al. Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction. Neuropharmacology. 2014;85:18–26. https://doi.org/10.1016/j.neuropharm.2014.05.007.CrossRefPubMed

28.

Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol. 2012;72(3):373–84. https://doi.org/10.1002/ana.23602.CrossRefPubMed

29.

Pang H, Huang T, Song J, Li D, Zhao Y, Ma X. Inhibiting HMGB1 with glycyrrhizic acid protects brain injury after DAI via its anti-inflammatory effect. Mediators Inflamm. 2016;2016:4569521. https://doi.org/10.1155/2016/4569521.CrossRefPubMedPubMedCentral

30.

Nishibori M, Wang D, Ousaka D, Wake H. High mobility group box-1 and blood-brain barrier disruption. Cells. 2020;9(12):2650. doi:https://doi.org/10.3390/cells9122650.

31.

Chou DK, Zhang J, Smith FI, McCaffery P, Jungalwala FB. Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. J Neurochem. 2004;90(6):1389–401. https://doi.org/10.1111/j.1471-4159.2004.02609.x.CrossRefPubMed

32.

Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000;275(51):40096–105. https://doi.org/10.1074/jbc.M006993200.CrossRefPubMed

33.

Xue X, Chen X, Fan W, Wang G, Zhang L, Chen Z, et al. High-mobility group box 1 facilitates migration of neural stem cells via receptor for advanced glycation end products signaling pathway. Scientific Reports. 2018;8(1):4513. https://doi.org/10.1038/s41598-018-22672-4.CrossRefPubMedPubMedCentral

34.

Okuma Y, Wake H, Teshigawara K, Takahashi Y, Hishikawa T, Yasuhara T, et al. Anti-high mobility group box 1 antibody therapy may prevent cognitive dysfunction after traumatic brain injury. World Neurosurg. 2019;122:e864–e71. https://doi.org/10.1016/j.wneu.2018.10.164.CrossRefPubMed

35.

Su X, Wang H, Zhao J, Pan H, Mao L. Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-kappaB pathway after traumatic brain injury in the rat. Mediators Inflammation. 2011;2011:807142. https://doi.org/10.1155/2011/807142.CrossRef

36.

Evran S, Calis F, Akkaya E, Baran O, Cevik S, Katar S, et al. The effect of high mobility group box-1 protein on cerebral edema, blood-brain barrier, oxidative stress and apoptosis in an experimental traumatic brain injury model. Brain Res Bull. 2020;154:68–80. https://doi.org/10.1016/j.brainresbull.2019.10.013.CrossRefPubMed

37.

Gu XJ, Xu J, Ma BY, Chen G, Gu PY, Wei D, et al. Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism. Chin J Traumatol = Zhonghua chuang shang za zhi. 2014;17(1):1–7.PubMed

38.

Aneja RK, Alcamo AM, Cummings J, Vagni V, Feldman K, Wang Q, et al. Lack of benefit on brain edema, blood-brain barrier permeability, or cognitive outcome in global inducible high mobility group box 1 knockout mice despite tissue sparing after experimental traumatic brain injury. J Neurotrauma. 2019;36(2):360–9. https://doi.org/10.1089/neu.2018.5664.CrossRefPubMed

39.

Armstrong RC, Mierzwa AJ, Sullivan GM, Sanchez MA. Myelin and oligodendrocyte lineage cells in white matter pathology and plasticity after traumatic brain injury. Neuropharmacology. 2016;110(Pt B):654–9. https://doi.org/10.1016/j.neuropharm.2015.04.029.CrossRefPubMed

40.

•• Ved R, Sharouf F, Harari B, Muzaffar M, Manivannan S, Ormonde C, et al. Disulfide HMGB1 acts via TLR2/4 receptors to reduce the numbers of oligodendrocyte progenitor cells after traumatic injury in vitro. Sci Rep. 2021;11(1):6181. https://doi.org/10.1038/s41598-021-84932-0Seminal in vitro study demonstrating a detrimental effect of HMGB1 on oligodendrocyte progenitor cells via TLR2/4 following traumatic injury. Indicates that extensive HMGB1 release post-injury may hinder recovery through impaired white matter repair.CrossRefPubMedPubMedCentral

41.

Gao TL, Yuan XT, Yang D, Dai HL, Wang WJ, Peng X, et al. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J Trauma Acute Care Surg. 2012;72(3):643–9. https://doi.org/10.1097/TA.0b013e31823c54a6.CrossRefPubMed

42.

Hung CH, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, et al. A randomized controlled trial of glycyrrhizin plus tenofovir vs. tenofovir in chronic hepatitis B with severe acute exacerbation. Clin Transl Gastroenterol. 2017;8(6):e104. https://doi.org/10.1038/ctg.2017.29.CrossRefPubMedPubMedCentral

43.

Xu W, Li Y, Ju M, Lai W, Lu X, Shi H, et al. A multicenter, randomized, double-blind, placebo-controlled study of compound glycyrrhizin capsules combined with a topical corticosteroid in adults with chronic eczema. Evid Based Complement Alternat Med. 2020;2020:6127327. https://doi.org/10.1155/2020/6127327.CrossRefPubMedPubMedCentral

44.

Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regulatory Toxicol Pharmacol: RTP. 2006;46(3):167–92. https://doi.org/10.1016/j.yrtph.2006.06.002.CrossRefPubMed

45.

Lin C-C, Weng M-T, Chung C-S, Liang C-C. The dramatic effect of intravenous glycyrrhizin on acute-on-chronic hepatic failure in chronic hepatitis B patients without liver cirrhosis. Advances Digestive Med. 2019;6(4):153–7. https://doi.org/10.1002/aid2.13131.CrossRef

46.

Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP. Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Critic Care Med. 2001;29(8):1513–8. https://doi.org/10.1097/00003246-200108000-00003.CrossRef

47.

Shin JH, Kim ID, Kim SW, Lee HK, Jin Y, Park JH, et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium. Mol Med. 2015;20(1):649–57. https://doi.org/10.2119/molmed.2014.00039.CrossRefPubMedPubMedCentral

48.

Shi H, Wang HL, Pu HJ, Shi YJ, Zhang J, Zhang WT, et al. Ethyl pyruvate protects against blood-brain barrier damage and improves long-term neurological outcomes in a rat model of traumatic brain injury. CNS Neurosci Therapeutics. 2015;21(4):374–84. https://doi.org/10.1111/cns.12366.CrossRef

49.

Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Internal Med. 2007;261(4):349–62. https://doi.org/10.1111/j.1365-2796.2007.01789.x.CrossRefPubMed

50.

Yang L, Wang F, Yang L, Yuan Y, Chen Y, Zhang G, et al. HMGB1 a-box reverses brain edema and deterioration of neurological function in a traumatic brain injury mouse model. Cell Physiol Biochem. 2018;46(6):2532–42. https://doi.org/10.1159/000489659.CrossRefPubMed

51.

Walker D, Lue LF, Paul G, Patel A, Sabbagh MN. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24(3):393–9. https://doi.org/10.1517/13543784.2015.1001490.CrossRefPubMedPubMedCentral

Titel: The Role of HMGB1 in Traumatic Brain Injury—Bridging the Gap Between the Laboratory and Clinical Studies
verfasst von: S Manivannan
E Wales
M Zaben
Publikationsdatum: 01.12.2021
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 12/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01158-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

The Molecular Neuroimaging of Tremor

Diagnostic Delay in Epilepsy: the Scope of the Problem

Self-awareness in Dementia: a Taxonomy of Processes, Overview of Findings, and Integrative Framework

Neurologic Complications of Cancer Therapies

Epidemiology of Brain and Other CNS Tumors